Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.

Next Previous
Trial Profile

A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms RAPID-C OLE
  • Sponsors UCB Pharma SA

Most Recent Events

  • 22 Jul 2019 According to the UCB media release, the company has received an Import Drug License (IDL) from the National Medical Product Administration (NMPA) and approval of CIMZIA (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis, based on the data from ths study.
  • 30 Mar 2018 According to the UCB media release, based on the data from this study, company announced the submission of an application for an Import Drug License to the Chinese Food and Drug Administration for the approval of CIMZIA (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis.
  • 16 Jan 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top